Markets:

Overview

News

Currencies

International

Treasuries

SELLAS Life Sciences Group, Inc. - Common Stock (NQ:SLS)

3.745 +0.435 (+13.14%)

Streaming Delayed Price Updated: 1:14 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about SELLAS Life Sciences Group, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Why Is SLS Stock Drawing Significant Investor Attention Today? ↗

Today 11:28 EST

Maxim analyst Jason McCarthy noted that because the trial is event-driven rather than time-driven, slower accrual of deaths can simply reflect longer patient survival, a positive sign for the...

Via Stocktwits

Topics Death

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

Via MarketMinute

Topics ETFs Intellectual Property

SELLAS Life Sciences Group Stock Soars As It Nears Final Analysis In Cancer Study ↗

December 29, 2025

The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred.

Via Stocktwits

Topics Death

Why Is SELLAS Life Sciences Stock Falling Today? ↗

October 27, 2025

Via Stocktwits

SLS Stock Has Risen 78% In A Month — What’s The Retail Buzz About? ↗

December 24, 2025

Retail investors are actively discussing recent clinical trials and the potential for a buyout or takeover.

Via Stocktwits

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

December 24, 2025

Issued on behalf of GT Biopharma, Inc.

From Equity Insider

Via GlobeNewswire

These stocks are gapping in today's session ↗

December 23, 2025

The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

SELLAS Life Sciences Stock Has Doubled This Year – Here’s Why Retail Investors Are Bullish ↗

December 17, 2025

The results from the company’s Phase 2 clinical trial for the investigational drug SLS009 and the Phase 3 REGAL trial, a survival-driven study of galinpepimut-S (GPS), are garnering interest.

Via Stocktwits

Topics Death

SELLAS Life Sciences Draws Retail Buzz On SLS009 Trial Momentum – Stock Soars In Pre-Market ↗

December 08, 2025

The trial involved combining SLS009 with azacitidine and venetoclax in patients with relapsed or refractory acute myeloid leukemia.

Via Stocktwits

Topics Artificial Intelligence

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 11, 2025

Via Benzinga

Papa John's Is Not First: Here Are 3 Other Stocks Rocked By Market-Moving Fake News ↗

November 11, 2025

Papa John's (PZZA) stock surged from a fake news hoax. It's not the first. See 3 other stocks, like Vinci & Avon, hit by market scams.

Via Benzinga

These stocks are moving in today's after hours session ↗

October 20, 2025

Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

Sellas Life Sciences Stock Jumps Over 7% Premarket: Buzz Builds Ahead Of Weekend Cancer Drug Presentation In Berlin ↗

October 16, 2025

The company said its cancer drug SLS009 showed strong preclinical results in T-cell prolymphocytic leukemia, improving survival and reducing tumor burden both alone and in combination with venetoclax.

Via Stocktwits

SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment ↗

October 13, 2025

SELLAS said that in a study model, SLS009 monotherapy and the combination prolonged overall survival compared to Venetoclax alone, with a statistically significant difference.

Via Stocktwits

Sellas Life Sciences Stock In Spotlight After Institutional Investor Exercises Existing Warrants ↗

September 11, 2025

In consideration for the immediate exercise of the warrants in full, the institutional investor will receive new, unregistered warrants in a private placement to purchase up to 19.69 million shares of...

Via Stocktwits

SELLAS Life Sciences Group Inc (NASDAQ:SLS) Reports Q2 2025 Earnings: Narrower Loss and Clinical Progress Amid Revenue Challenges ↗

August 12, 2025

SELLAS Life Sciences (SLS) reported Q2 2025 EPS of -$0.07, beating estimates, with no revenue. Cash position strengthened to $25.3M. Clinical trials progress highlighted, including REGAL Phase 3 AML...

Via Chartmill

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

June 24, 2025

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INDP),(NYSE:CATX),(NASDAQ:SLS),(NASDAQ:AUTL EQNX::TICKER_END

Via FinancialNewsMedia

Thursday's after hours session: top gainers and losers ↗

May 22, 2025

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Top movers in Tuesday's after hours session ↗

May 13, 2025

The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today.

Via Chartmill

Wondering what's happening in today's after-hours session? ↗

April 08, 2025

As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

What's going on in today's after hours session ↗

January 30, 2025

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

These stocks are moving in today's session ↗

January 27, 2025

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

8 Health Care Stocks Whale Activity In Today's Session ↗

January 20, 2025

Via Benzinga

SLS Stock Earnings: SELLAS Life Sciences Gr Beats EPS for Q2 2024 ↗

August 13, 2024

SLS stock results show that SELLAS Life Sciences Gr beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 17, 2024

Via Benzinga

Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

June 17, 2024

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q1 2024 ↗

May 14, 2024

SLS stock results show that SELLAS Life Sciences Gr missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 29, 2024

Via Benzinga

Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

June 17, 2024

From FN Media Group LLC

Via GlobeNewswire

SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q4 2023 ↗

March 28, 2024

SLS stock results show that SELLAS Life Sciences Gr missed analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.